The RAMP cardiovascular product line includes Troponin I, CK-MB, Myoglobin and NT-proBNP Tests. The company is awaiting FDA 510(k) clearance before the NT-proBNP Test can be sold in the US.
Roche Diagnostics’ comprehensive sales and marketing infrastructure is expected to allow for broad worldwide penetration of Response Biomedical’s cardiovascular line.
Wayne Kay, CEO of Response Biomedical, said: “This collaboration significantly enhances our commercialization strategy and sets the stage for rapid market expansion. Furthermore, we are exploring the application of our proprietary RAMP platform to other clinical areas where its unique advantages can be leveraged to improve patient care.”